Jean Combalbert
Amministratore Delegato presso Ogeda SA
Posizioni attive di Jean Combalbert
Società | Posizione | Inizio | Fine |
---|---|---|---|
Ogeda SA
Ogeda SA Pharmaceuticals: MajorHealth Technology Ogeda SA discovers and develops small molecule drugs. It develops NK3 antagonists for the treatment of hormone-dependent pathologies in the field of Women's Health. The company was founded in 1994 and is headquartered in Gosselies, Spain. | Direttore/Membro del Consiglio | - | - |
Amministratore Delegato | - | - | |
Epics Therapeutics SA
Epics Therapeutics SA Miscellaneous Commercial ServicesCommercial Services EPICS Therapeutics SA engages in the development of therapeutic solutions for cancer. The company was founded by Jean Combalbert, Alain Parthoens and Francois Fuks on February 20, 2018 and is headquartered in Charleroi, Belgium. | Direttore/Membro del Consiglio | 20/02/2018 | - |
Fondatore | 20/02/2018 | - | |
Syndesi Therapeutics SA
Syndesi Therapeutics SA Miscellaneous Commercial ServicesCommercial Services Syndesi Therapeutics SA develops novel therapeutics for cognitive impairment which includes Alzheimer’s disease, dementias, and cognitive impairment associated with schizophrenia. The company is headquartered in Louvain-la-Neuve, Belgium. | Presidente | - | - |
Storia della carriera di Jean Combalbert
Precedenti posizioni note di Jean Combalbert
Società | Posizione | Inizio | Fine |
---|---|---|---|
PHARNEXT SCA | Direttore/Membro del Consiglio | 17/07/2020 | 15/07/2021 |
Entomed SA
Entomed SA Pharmaceuticals: MajorHealth Technology Entomed SA discovers and develops novel medicines derived from insects. It discovers and develops new drugs derived from the biology of insects with a focus on their immune response. Entomed's technology is based on the scientific work carried out by Prof. Jules A. Hoffmann's world leading team in the CNRS Institute of Molecular and Cellular Biology (IBMC) in Strasbourg. The company was founded in 1999 and is headquartered in Illkirch-Graffenstaden, France. | Presidente | 03/02/2009 | 03/02/2009 |
Presidente | - | 03/02/2009 | |
Bioxodes SA
Bioxodes SA Pharmaceuticals: MajorHealth Technology Bioxodes SA develops pharmaceutical products. Its programme Ir-CPI, is the first in a novel class of antithrombotics, and is developed for the prevention of thrombosis in a range of applications including cardiopulmonary bypass grafting and percutaneous coronary intervention. The company was founded by Edmond Godfroid and Michel Guyaux on April 20, 2010 and is headquartered in Marche-en-Famenne, Belgium. | Presidente | - | - |
SANOFI | Corporate Officer/Principal | - | - |
Formazione di Jean Combalbert
University of Marseille | Doctorate Degree |
Statistiche
Distribuzione geografica
Francia | 5 |
Belgio | 5 |
Posizioni
Director/Board Member | 3 |
Chairman | 3 |
Chief Executive Officer | 1 |
Settori
Health Technology | 6 |
Commercial Services | 3 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 2 |
---|---|
SANOFI | Health Technology |
PHARNEXT SCA | Health Technology |
Aziende private | 5 |
---|---|
Entomed SA
Entomed SA Pharmaceuticals: MajorHealth Technology Entomed SA discovers and develops novel medicines derived from insects. It discovers and develops new drugs derived from the biology of insects with a focus on their immune response. Entomed's technology is based on the scientific work carried out by Prof. Jules A. Hoffmann's world leading team in the CNRS Institute of Molecular and Cellular Biology (IBMC) in Strasbourg. The company was founded in 1999 and is headquartered in Illkirch-Graffenstaden, France. | Health Technology |
Ogeda SA
Ogeda SA Pharmaceuticals: MajorHealth Technology Ogeda SA discovers and develops small molecule drugs. It develops NK3 antagonists for the treatment of hormone-dependent pathologies in the field of Women's Health. The company was founded in 1994 and is headquartered in Gosselies, Spain. | Health Technology |
Bioxodes SA
Bioxodes SA Pharmaceuticals: MajorHealth Technology Bioxodes SA develops pharmaceutical products. Its programme Ir-CPI, is the first in a novel class of antithrombotics, and is developed for the prevention of thrombosis in a range of applications including cardiopulmonary bypass grafting and percutaneous coronary intervention. The company was founded by Edmond Godfroid and Michel Guyaux on April 20, 2010 and is headquartered in Marche-en-Famenne, Belgium. | Health Technology |
Syndesi Therapeutics SA
Syndesi Therapeutics SA Miscellaneous Commercial ServicesCommercial Services Syndesi Therapeutics SA develops novel therapeutics for cognitive impairment which includes Alzheimer’s disease, dementias, and cognitive impairment associated with schizophrenia. The company is headquartered in Louvain-la-Neuve, Belgium. | Commercial Services |
Epics Therapeutics SA
Epics Therapeutics SA Miscellaneous Commercial ServicesCommercial Services EPICS Therapeutics SA engages in the development of therapeutic solutions for cancer. The company was founded by Jean Combalbert, Alain Parthoens and Francois Fuks on February 20, 2018 and is headquartered in Charleroi, Belgium. | Commercial Services |
- Borsa valori
- Insiders
- Jean Combalbert
- Esperienza